Ceftazidima

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceftazidima

Ceftazidima is the international non-proprietary name (INN) for the active substance Ceftazidime, a powerful semisynthetic beta-Lactam antibiotic used to eliminate susceptible bacterial infections. It is strictly classified as a third-generation cephalosporin, distinguishing it by its stability and expanded scope against many serious Gram-negative bacteria.

Property Description
Active Ingredient Ceftazidime
Form Sterile powder for solution for injection
Pharmacological Class Third-generation cephalosporin antibiotic
Common Use Bactericidal elimination of susceptible bacteria
Origin Semisynthetic

Defining Ceftazidima: What Type of Antibiotic Is It?

Ceftazidima belongs to the cephalosporin family of antibiotics, a class defined by a core chemical structure that targets the integrity of bacterial cells. It is a single-ingredient product, typically prepared using the compound Ceftazidime Pentahydrate. This agent functions as a potent bactericidal agent, meaning it actively kills the target bacteria rather than merely inhibiting their growth. This classification is clinically recognized for its effectiveness against many hospital-acquired infections, positioning it as a key option when managing serious systemic bacterial challenges.


Form and Preparation: How Ceftazidima is Supplied

Ceftazidima is primarily supplied as a sterile powder for solution for injection, indicating that it is not available as a common oral medicine. This physical form is intended exclusively for parenteral administration, meaning it must be given directly into the body, typically through intravenous (IV) infusion or intramuscular (IM) injection. The active powder requires immediate reconstitution with a sterile liquid solvent, such as water for injection or saline, which creates the final solution used for delivery. This administration method ensures a high, predictable concentration of Ceftazidime is rapidly available in the bloodstream to fight systemic infections effectively, a critical feature for treating severe bacterial diseases.


General Purpose: Why Ceftazidime is Used

The general purpose of Ceftazidime is the rapid destruction of susceptible bacteria, providing systemic therapeutic relief. The drug's mechanism involves binding to specific enzymes called penicillin-binding proteins (PBPs), which blocks the bacteria’s ability to maintain its protective cell wall. This fundamental action causes the microbial cell structure to fail and rupture, achieving the desired bactericidal effect. This potent, targeted action makes Ceftazidime suitable for eliminating a wide array of serious, often resistant, Gram-negative bacteria, making it typically used as a foundational tool for managing complicated infections of the lungs, skin, or bloodstream.

Regulatory References

  1. Ceftazidime Injection: MedlinePlus Drug Information
  2. CEFTAZIDIME injection: DailyMed

What side effects are possible with Ceftazidima?

Possible Side Effects and Safety Information

Ceftazidima is generally well-tolerated, with most documented adverse reactions being mild. However, the drug carries a risk for several serious and clinically significant adverse reactions that are noted in regulatory safety documents.


Key Adverse Reactions and Frequencies

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Documented)
Gastrointestinal Diarrhea, Nausea, Vomiting Clostridioides difficile-Associated Diarrhea (CDAD)/Colitis
Immune System Rash, Pruritus (itching), Urticaria Anaphylaxis, Severe Allergic Reactions (e.g., SJS, TEN)
Nervous System Headache, Dizziness Seizures, Encephalopathy, Myoclonus, Coma
Blood & Lymphatic Eosinophilia, Thrombocytosis Hemolytic Anemia, Coagulopathy (Prothrombin Time Prolongation)

Common adverse reactions typically involve the gastrointestinal system and local site reactions (e.g., pain, inflammation at the injection site). Other reported events include increases in liver enzymes and a positive Coombs test.


Safety Considerations and Restrictions

  • Renal Impairment: Ceftazidima is primarily excreted by the kidneys. Patients with impaired renal function are at significantly increased risk for neurologic adverse reactions, including seizures, encephalopathy, and myoclonus, due to elevated and prolonged serum concentrations of the drug. Dosage adjustment is mandatory in this population.
  • Hypersensitivity: The drug is contraindicated in individuals with a known severe allergy to ceftazidime or other cephalosporin antibiotics. Caution is required for patients with a history of penicillin allergy due to potential cross-hypersensitivity.
  • Overgrowth: Prolonged use carries the risk of overgrowth of non-susceptible organisms, including fungi or Clostridioides difficile bacteria, which can lead to superinfection or severe colitis (CDAD).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Ceftazidima overdosage is focused on severe neurological effects and risks associated with impaired drug clearance. The U.S. Food and Drug Administration (FDA) Prescribing Information confirms that overdosage has occurred in patients with renal failure.

Documented Overdose Manifestations

Acute overdosage is documented to present with serious neurological events, including seizure activity, encephalopathy, asterixis (flapping tremor), neuromuscular excitability, and coma. The occurrence of these severe manifestations requires immediate medical attention.


Required Emergency Actions

Official labeling mandates specific actions following an acute overdosage. Patients should be carefully observed and provided with supportive treatment. In the context of renal insufficiency, official documents describe that procedural measures such as hemodialysis or peritoneal dialysis may aid in the removal of ceftazidime from the body. There is no specific antidote listed in the regulatory information.

Therapeutic Uses of Ceftazidima

Ceftazidima is used to provide therapeutic support by managing susceptible pathogens in cases of severe and complicated bacterial illness. It is commonly used in clinical settings that involve acute or unstable symptom patterns to offer systemic relief and address symptoms caused by difficult-to-treat infections.

This medication is relevant for conditions presenting with systemic or localized discomfort across domains like severe pneumonia, septicemia (blood poisoning), meningitis, intra-abdominal infections, and infections of the bone and urinary tract. It is applied across domains where additional symptomatic support is needed, particularly when managing infections caused by challenging bacteria.

“Ceftazidima assists with maintaining functional stability during difficult episodes by providing support that helps ease the overall symptom burden.”

This supportive relief is relevant for easing acute symptoms, including intense, persistent fever and chills (symptoms related to systemic imbalance), severe headache, and deep-seated pain and swelling. It is also commonly used to help with acute infections in neonates and immunocompromised patients.


Quick Fact: Relief for Acute Systemic Symptoms

This medication plays a role in managing symptoms that create noticeable physiological strain by assisting with managing the acute, high fever and chills that often signal a severe, escalating infection. This supportive relief is relevant in contexts involving heightened systemic burden.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Ceftazidima (Ceftazidime) eligibility is determined by official regulatory documents, focusing primarily on hypersensitivity status, renal function, and patient age.

Contraindicated Populations

Use is contraindicated in patients with a documented history of severe hypersensitivity to Ceftazidime, the cephalosporin class, or any other beta-lactam antibacterial agents, such as penicillins.

Age-Related Eligibility and Restrictions

Age Group Regulatory Status
Adults & Children Established as eligible from birth (neonates)
Older Adults Generally eligible, but dosage should be carefully monitored due to age-related decline in renal clearance.
Infants le 2 Months Safety and efficacy for continuous infusion are not established.

Conditional Use and Comorbidity Rules

Ceftazidima requires conditional use in patients with impaired renal function or reduced urinary output. Since the drug is cleared through the kidneys, the official label mandates dosage adjustment in these patients to prevent neurological toxicity. Caution is also advised for individuals with a history of gastrointestinal disease, particularly colitis.

Pregnancy and Lactation Status

Use during pregnancy is permitted only when the benefit is judged to outweigh the risk to the fetus (US FDA Category B). The drug is excreted in human milk at low levels, and use during lactation is generally considered acceptable.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ceftazidima is characterized by risks of additive organ toxicity, potential antagonism, and specific analytical interference.


Pharmacodynamic and Toxicity Interactions

Co-administration with Aminoglycoside Antibiotics (such as Gentamicin or Amikacin) or Potent Diuretics carries an officially documented increased potential for nephrotoxicity and ototoxicity. This requires careful monitoring during concurrent use. Regulatory documents advise that the combination of Ceftazidima and Chloramphenicol should be avoided due to observed antagonistic effects in vitro that may compromise the intended bactericidal action. Additionally, Ceftazidima has been documented to reduce the efficacy of Combined Oral Contraceptives.

Clearance and Exposure Profile

Unlike certain other antibacterials, Ceftazidima’s elimination kinetics are not affected by Probenecid, confirming that the medicine is cleared by glomerular filtration and not active renal tubular secretion. Due to its non-metabolized, renal-exclusive clearance, patients with impaired renal function experience a significantly prolonged half-life and increased drug exposure.

Diagnostic Interference

Ceftazidima may result in a false-positive reaction for glucose in the urine when tested using non-enzymatic methods like CLINITEST, Benedict's, or Fehling's solutions. Regulatory guidance mandates that alternative tests based on enzymatic glucose oxidase reactions must be used to ensure accurate results.

Mechanism of Action

How Ceftazidime Works

Ceftazidime initiates a bactericidal action by targeting and irreversibly inhibiting specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs), primarily PBP3, which are located in the cell wall. The drug's structure acts as a structural mimic of the enzymes' natural substrate, allowing it to covalently bind to the PBP active site and permanently disable its function. This molecular deactivation stops the transpeptidation process required for peptidoglycan cross-linking.

The sudden failure of the cross-linking pathway and the inhibition of PBP3's role in septum formation (cell division) results in a structurally defective bacterial cell wall. This disruption causes the structurally weak wall to fail against the high internal osmotic pressure of the bacteria, leading to the activation of bacterial autolytic enzymes. This cascade of events culminates in the rupture of the microbial cell (lysis), which is the necessary physiological consequence of the mechanism.

The molecule possesses an inherent stability against hydrolysis by many common bacterial beta-lactamases, meaning the drug's structure resists enzymatic deactivation. However, the mechanism is constrained by evolving resistance, such as the production of specific Extended-Spectrum beta-Lactamases (ESBLs), which can break down the drug, or mutations that reduce its binding affinity to the PBP targets.

Dosage and Administration Information

How Ceftazidima is Used: Administration Guidelines

Ceftazidima (Ceftazidime) is a single-ingredient antibiotic supplied as a sterile powder for solution that is intended exclusively for parenteral administration. The instructions for use define the precise method of preparation, delivery, and necessary dose adjustments.

Administration Scope Requirement
Route of Administration Intravenous (IV) injection (bolus over 3 -5 minutes or infusion over 20 -30 minutes) or Intramuscular (IM) injection.
Standard Dosing Schedule Doses for most adult infections range from 1 g every 8 hours to 2 g every 12 hours. For very severe or life-threatening infections, 2 g every 8 hours may be prescribed.
Preparation Requirement The sterile powder must be reconstituted with a specific diluent before use. The resulting solution is typically clear and may range in color from light yellow to amber.

Population-Specific Instructions

Guidelines include adjustments for specific patient groups:

  • Renal Impairment: Because the medicine is excreted primarily by the kidneys, the dose or frequency must be reduced based on the patient's calculated Creatinine Clearance (CrCl).
  • Older Adults: For patients over 80 years of age, the total daily dose should generally not exceed 3 g.
  • Pediatric Dosing: Dosing for children (over two months) is based on body weight, typically 30 -100 mg/kg/day divided into two or three doses.

These guidelines establish a precise protocol for clinical use, ensuring the correct amount is delivered at the proper interval and by the approved route, with necessary adjustments for clearance.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Recent clinical research involving Ceftazidima primarily focuses on its use in combination with the beta-lactamase inhibitor avibactam (Ceftazidime-avibactam, CAZ-AVI). This combination is studied to address infections caused by multi-drug resistant Gram-negative bacteria, including those producing certain extended-spectrum beta-lactamases (ESBLs) and carbapenemases.


Efficacy in Resistant Infections

Phase 3 clinical trials have evaluated Ceftazidime-avibactam for several serious indications. Studies examining the compound for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) have reported findings that suggest outcomes comparable to carbapenem therapies in hospitalized patients. For cIAI, the combination was studied in conjunction with metronidazole.

Real-world observational studies examining Ceftazidime-avibactam's use against Carbapenem-Resistant Enterobacterales (CRE) have also been conducted. These reports suggest favorable clinical and microbiological outcomes in a percentage of treated patients, particularly those with difficult-to-treat infections. Study findings for patients with complicated pneumonia (including ventilator-associated pneumonia) have also been reported.


Safety Profile and Research Gaps

Research continues to explore the safety profile of the Ceftazidime-avibactam combination. Adverse events reported in trials have typically been consistent with those expected for cephalosporins, such as gastrointestinal events and headache.

Evidence remains limited on the comparative benefit of Ceftazidime-avibactam monotherapy versus combination regimens for certain highly resistant pathogens, such as multi-drug resistant Pseudomonas aeruginosa. Further randomized controlled trials may be required to clarify the role of combination regimens.

Frequently Asked Questions (FAQ)

Common questions about Ceftazidima (FAQ)

Q: If I miss a dose of Ceftazidime, what should I do?

A: Official regulatory information indicates that if a dose is missed, it may be administered as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the regular dosing schedule should be continued. It is important that a double dose is not administered to try to make up for a missed one.

Q: Does this medicine come as a pill or a liquid you can drink?

A: According to the official product information, Ceftazidime is supplied only as a sterile powder for solution for injection. This powder is intended for parenteral administration, meaning it is given directly into the body, typically through an intravenous (IV) or intramuscular (IM) injection. The medicine is not available in a common oral pill or liquid form for consumption.

Q: How long after starting the medication should I expect to feel better?

A: Regulatory patient information suggests that an improvement in symptoms is typically expected during the first few days after beginning treatment. If an individual does not notice any improvement, or if symptoms appear to worsen, it is important to consult a healthcare provider for further evaluation.

Q: How long does Ceftazidime stay in my system after the last dose?

A: For patients with normal kidney function, Ceftazidime has an elimination half-life of approximately 1.9 to 2 hours. The medicine is eliminated from the body almost entirely (about 80% to 90%) unchanged by the kidneys. This profile indicates that the drug is cleared through the kidneys at a predictable rate.

How should Ceftazidima be stored and disposed of?

How to Store and Dispose of Ceftazidima

The sterile dry powder form of Ceftazidima must be stored at Controlled Room Temperature (20 C to 25 C) and kept protected from light. The product must be stored out of the sight and reach of children.


Stability and Storage Constraints

Product Form Storage Temperature Maximum Stable Period
Dry Powder 20 C to 25 C According to labeled expiry
Reconstituted Solution 2 C to 8 C (Refrigerated) Up to 7 days
Reconstituted Solution 20 C to 25 C Up to 24 hours

Frozen solutions must not be refrozen after thawing. Unused or expired Ceftazidima must be disposed of according to local, regional, and national regulations for pharmaceutical waste, typically directed to a hazardous or special waste collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceftazidima found in:

A-Z Index: